← Leaderboards
Sangkon Oh
Baylor Research Institute
$3,218,826
Attributed
$3,218,826
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $601.4K · FY2010–18$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$3,218,826 · 4
By mechanism
R01$1,921,586 · 1
RC1$499,875 · 1
R21$428,885 · 1
R56$368,480 · 1
Top collaborators
No co-investigators on record.
Most similar at Baylor Research Institute
Same institution · by research overlap
- Hideki Ueno$3,505,409
- Gerard Zurawski$3,785,315
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroAntigensSkinT-LymphocyteImmune ResponseAntigen-Presenting CellsNonhuman PrimateResponseTissuesDendritic CellsIn VivoDesignReceptorEffectivenessPreventPreventionNovel TherapeuticsPathogenProgramsCytokineLectinMemoryInfectionMolecular
Grant awards (9)
DC-ASGPR as Novel Target for Controlling GVHD and Allograft Rejection$415,000
R01 · FY2018 · AI · contact PI
DC-ASGPR as Novel Target for Controlling GVHD and Allograft Rejection$392,000
R01 · FY2017 · AI · contact PI
DC-ASGPR as Novel Target for Controlling GVHD and Allograft Rejection$392,000
R01 · FY2016 · AI · contact PI
DC-ASGPR as Novel Target for Controlling GVHD and Allograft Rejection$392,000
R01 · FY2015 · AI · contact PI
DC-ASGPR as Novel Target for Controlling GVHD and Allograft Rejection$330,586
R01 · FY2014 · AI · contact PI
DC-ASGPR AS A NOVEL TARGET FOR CONTROLLING GVHD AND ALLOGRAFT REJECTION$368,480
R56 · FY2013 · AI · contact PI
Controlling Allergen-specific Th2-type Responses by Targeting DC Surface Lectins$232,885
R21 · FY2013 · AI · contact PI
Controlling Allergen-specific Th2-type Responses by Targeting DC Surface Lectins$196,000
R21 · FY2012 · AI · contact PI
Targeting Dendritic Cell Subsets in Human Vagina to Elicit Local Immunity$499,875
RC1 · FY2010 · AI · contact PI